scispace - formally typeset
T

Tilman B. Drüeke

Researcher at French Institute of Health and Medical Research

Publications -  415
Citations -  22817

Tilman B. Drüeke is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Kidney disease & Hyperparathyroidism. The author has an hindex of 68, co-authored 413 publications receiving 21471 citations. Previous affiliations of Tilman B. Drüeke include Versailles Saint-Quentin-en-Yvelines University & University of Paris-Sud.

Papers
More filters
Journal ArticleDOI

Fibroblast growth factor receptor 4: the missing link between chronic kidney disease and FGF23-induced left ventricular hypertrophy?

TL;DR: Serum phosphorus and the regulatory hormone fibroblast growth factor 23 have been strongly linked to cardiovascular morbidity and mortality in patients with chronic kidney disease and a recent study identified fibro Blast growth factor receptor 4 as the primary receptor mediating the effect on left ventricular hypertrophy.
Journal ArticleDOI

Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graphe3 study.

TL;DR: Less than 20% of patients with chronic kidney disease undergoing intermittent haemodialysis achieved the KDIGO recommendations although their proportion increased slightly over time, while no significant change was observed for those with controlled PTH.
Journal ArticleDOI

Genetic Aspects of Secondary Hyperparathyroidism in Uremia

TL;DR: The frequent transformation of parathyroid cell proliferation from polyclonal to monoclonal growth in patients with severe secondary hyperparathyroidism must be attributed to mutations or deletions of various tumor-suppressor genes, and probably more rarely also to an activation of tumor-enhancer genes.
Journal ArticleDOI

Effect of type of dialysis membrane on bone in haemodialysis patients

TL;DR: In this article, the authors conducted a prospective, open study in 24 chronic haemodialysis patients who were randomized to dialysis treatment with either cellulosic (CELL) or polyacrylonitrile (AN-69) membrane for 9 months.